EverHint Lens - Kodiak Sciences Inc. ($KOD) - Yahoo Finance Top Gainer Stock (+59%) Analysis - March 26, 2026
Analysis Date: 2026-03-26
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Executive Summary
Kodiak Sciences Inc. is currently trading at $36.16 (🟢 +58.97% today) with a market capitalization of $1.91B.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Price & Valuation
Current Price: $36.16 (at 11:50 AM ET)
Current Volume: 8.0M
Day Range: $33.50 - $38.93
52-Week Range: $1.92 - $38.93
P/E Ratio: -8.80
DCF Valuation: Overvalued
- Intrinsic Value (Unlevered DCF): $1.79
- Current Price: $36.16
- Discount/Premium: -95.0%
Levered DCF: $1.86 (-94.9%)
DCF analysis suggests the stock may be trading at a 95.0% premium to its intrinsic value.
DCF values calculated as of 2026-03-26. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.
Market Context
Healthcare Sector: 1.07569% | Sector P/E: 26.52
Major Indices:
- S&P 500: $6542.17 (🔴 -0.75%)
- NASDAQ Composite: $21706.85 (🔴 -1.02%)
- Dow Jones Industrial Average: $46229.15 (🔴 -0.43%)
Peer Comparison
Peer comparison (11 companies):
- KOD - Kodiak Sciences Inc. ($36.16, +59.0%, $1.91B) ← Current
- TNGX - Tango Therapeutics, Inc. ($20.48, -1.9%, $2.38B)
- ANAB - AnaptysBio, Inc. ($66.24, +1.3%, $1.90B)
- OCS - Oculis Holding AG ($24.85, -0.6%, $1.42B)
- NRIX - Nurix Therapeutics, Inc. ($15.95, +3.3%, $1.38B)
- EYPT - EyePoint Pharmaceuticals, Inc. ($12.85, -1.5%, $1.07B)
- XNCR - Xencor, Inc. ($12.61, +1.7%, $925M)
- URGN - UroGen Pharma Ltd. ($18.03, -0.5%, $878M)
- PHAT - Phathom Pharmaceuticals, Inc. ($10.74, +2.6%, $847M)
- BBOT - BridgeBio Oncology Therapeutics Inc. ($9.35, +1.1%, $748M)
- PROK - ProKidney Corp. ($1.74, -5.2%, $502M)
Financial Performance
Latest Quarter (2025-09-30):
- Revenue: $0.00M
- Net Income: $-61.46M
- EPS: $-1.16
Stock Split History
KOD has executed 1 stock split(s) historically
- 2022-02-23: 5-for-1 split
Cumulative Split Factor: 5x (1 share in 1987 = 5 shares today)
Most recent split: 5-for-1 on 2022-02-23
Earnings Calendar
No upcoming earnings dates currently scheduled
Most Recent Report: 2026-03-26
Historical Data: 36 earnings events tracked
Analyst Outlook
Analyst Price Target Consensus:
- Target: $44.00 (+21.7% upside)
- Range: $38.00 - $50.00
- Median: $44.00
Next Quarter Estimates (2026-12-30):
- EPS: $-0.84
Analyst Consensus
Overall Rating: Hold
Rating Distribution (123 total ratings):
- 🟢 Buy/Outperform: 38 (30.9%)
- ⚪ Hold/Neutral: 44 (35.8%)
- 🔴 Sell/Underperform: 16 (13.0%)
Recent Analyst Actions:
- UBS (2026-01-07): Initiate Buy
- Jefferies (2025-09-22): Initiate Buy
- H.C. Wainwright (2026-01-22): Maintain Buy
- Barclays (2025-08-14): Maintain Underweight
Consensus based on 123 analyst ratings from major financial institutions
Trading Signals
Our technical analysis identified 2 trading signal(s) in the last 60 days:
- 2026-02-20: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $25.28
- 2026-02-19: Dip Bounce V2 Reclaim - RECLAIM_LONG @ $26.66
Insider Activity
Recent Transactions (Last 10):
- Buys: 9
- Sells: 0
Notable Transactions:
- 2026-03-18: PERLROTH VICTOR - Buy (Award, 175,000 shares @ $25.00)
- 2025-12-31: PERLROTH VICTOR - Other (, 0 shares)
- 2025-12-18: BAKER BROS. ADVISORS LP - Buy (Purchase, 2,391,268 shares @ $23.00)
Congressional Trading Activity
Tracking recent stock transactions by U.S. Congress members
House of Representatives: 2 transactions tracked
Recent Activity:
- ⚪ Chris Jacobs (NY27): Sale (Full) on 2022-11-08, Amount: $1,001 - $15,000
- 🟢 Chris Jacobs (NY27): Purchase on 2022-07-18, Amount: $1,001 - $15,000
Congressional trading data sourced from official disclosure filings
News Sentiment Analysis
AI Analysis (based on 30 recent articles):
Kodiak Sciences Inc. (KOD) shows strongly positive sentiment, highlighted by a 52% share surge following successful Phase 3 GLOW2 trial results for Zenkuda in diabetic retinopathy. Major institutional investments from Baker Bros. and Braidwell, insider buying, favorable analyst ratings, and pipeline advancements further fuel optimism. Minor stock dips and wider losses are overshadowed by funding raises and clinical progress.
Key Themes:
- Clinical Trial Success
- Institutional Investment
- Stock Performance Gains
Sentiment: Positive (92% confidence)
Recent News
5 most recent articles covering KOD:
- Kodiak Sciences shares surge after eye drug succeeds in late-stage study (reuters.com, 2026-03-26) — Read more
- Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham (prnewswire.com, 2026-03-26) — Read more
- Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing (fool.com, 2026-03-09) — Read more
- Kodiak Sciences Inc. (NASDAQ:KOD) Receives $28.29 Consensus Target Price from Brokerages (defenseworld.net, 2026-03-05) — Read more
- Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy (fool.com, 2026-02-23) — Read more
Full news analysis based on 30 recent articles
Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-26 08:50:09 AM PDT
Disclaimer: This is not investment advice. Always do your own research before making investment decisions.